Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Monday, 23'rd Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Granite Investment Partners LLC Has $16.38 Million Stock Position in Veracyte, Inc. $VCYT
04:04am, Monday, 23'rd Feb 2026
Granite Investment Partners LLC reduced its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 25.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange
Veracyte to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond Ja
Illinois Municipal Retirement Fund Takes Position in Veracyte, Inc. $VCYT
04:03am, Wednesday, 18'th Feb 2026
Illinois Municipal Retirement Fund acquired a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
09:56am, Monday, 16'th Feb 2026
VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.
Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Thursday, 05'th Feb 2026
The heavy selling pressure might have exhausted for Veracyte (VCYT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
05:15pm, Wednesday, 04'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and ful
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:46am, Wednesday, 04'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now
10:55am, Friday, 30'th Jan 2026
Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Wednesday, 28'th Jan 2026
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Veracyte, Inc. $VCYT Shares Purchased by Amalgamated Bank
03:08am, Tuesday, 27'th Jan 2026
Amalgamated Bank boosted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 755.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again
01:10pm, Monday, 26'th Jan 2026
Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:50am, Thursday, 22'nd Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Oregon Public Employees Retirement Fund Takes $608,000 Position in Veracyte, Inc. $VCYT
05:36am, Monday, 19'th Jan 2026
Oregon Public Employees Retirement Fund bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to the company in its most recent 13F filing with the Securities
Veracyte: Profitable, De-Risked, And Ready To Run
09:44am, Friday, 16'th Jan 2026
Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration
